The emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with sarcoidosis
The purpose of this article is to examine the emerging role of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with sarcoidosis.Materials and methods
We reviewed the literature on the use of FDG-PET in patients with sarcoidosis to identify how this technique is being applied in clinical practice.Results and discussion
Our review shows that: 1) sarcoidosis is commonly associated with increased FDG uptake. Therefore, positive findings should be interpreted with caution when FDG-PET is being used to distinguish benign from malignant abnormalities; 2) FDG-PET seems to be a very useful molecular imaging method for staging sarcoidosis, identification of occult sites of involvement, guiding biopsy procedures, and monitoring patients’ responses to treatment; and 3) in patients with sarcoidosis, the diagnostic accuracy of FDG-PET is superior to that of 67Ga scintigraphy.
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
Copyright (c) 2012 Silvia Taralli, Giorgio Treglia, Alessandro Giordano
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.